| 1. |
|
|
| 2. |
- Moorkens, E, et al.
(författare)
-
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
- 2021
-
Ingår i: Frontiers in pharmacology. - : Frontiers Media SA. - 1663-9812. ; 11, s. 591134-
-
Tidskriftsartikel (refereegranskat)abstract
- Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of this paper is to provide a European overview of (list) prices of originator adalimumab, before and after loss of exclusivity; to report changes in the reimbursement status of adalimumab products; and discuss relevant policy measures.Methods: Experts in European countries received a survey consisting of three parts: 1) general financing/co-payment of medicines, 2) reimbursement status and prices of originator adalimumab, and availability of biosimilars, and 3) policy measures related to the use of adalimumab.Results: In May 2019, adalimumab biosimilars were available in 24 of the 30 countries surveyed. Following introduction of adalimumab biosimilars, a number of countries have made changes in relation to the reimbursement status of adalimumab products. Originator adalimumab list prices varied between countries by a factor of 2.8 before and 4.1 after loss of exclusivity. Overall, list prices of originator adalimumab decreased after loss of exclusivity, although for 13 countries list prices were unchanged. When reported, discounts/rebates on originator adalimumab after loss of exclusivity ranged from 0% to approximately 26% (Romania), 60% (Poland), 80% (Denmark, Italy, Norway), and 80–90% (Netherlands), leading to actual prices per pen or syringe between €412 (Finland) and €50 – €99 (Netherlands). To leverage competition following entry of biosimilar adalimumab, only a few countries adopted measures specifically for adalimumab in addition to general policies regarding biosimilars. In some countries, a strategy was implemented even before loss of exclusivity (Denmark, Scotland), while others did not report specific measures.Conclusion: Even though originator adalimumab is the highest selling product in the world, few countries have implemented specific policies and practices for (biosimilar) adalimumab. Countries with biosimilars on the market seem to have competition lowering list or actual prices. Reported discounts varied widely between countries.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Egry, I., et al.
(författare)
-
Thermophysical properties of gamma-titanium aluminide : The European IMPRESS project
- 2007
-
Ingår i: International journal of thermophysics. - : Springer Science and Business Media LLC. - 0195-928X .- 1572-9567. ; 28:3, s. 1026-1036
-
Tidskriftsartikel (refereegranskat)abstract
- In the framework of its 6th Framework Programme, the European Union funds the Integrated Project IMPRESS, related to industrial applications of Ti-Al and Ni-Al alloys. One central task of this project is the precise determination of the relevant thermophysical properties of selected alloys for both the solid and liquid phases. The properties to be measured include thermal data such as heat of fusion, specific heat, and thermal conductivity, as well as thermophysical and transport properties such as density, surface tension, and viscosity. In addition to conventional high-temperature equipment, containerless methods are used. This article introduces the IMPRESS project, and discusses the first results obtained to date.
|
|
| 8. |
- Egry, I., et al.
(författare)
-
Thermophysical properties of liquid Al-Ni alloys
- 2009
-
Ingår i: High Temperatures-High Pressures. - 0018-1544 .- 1472-3441. ; 38:4, s. 343-351
-
Tidskriftsartikel (refereegranskat)abstract
- Within the Integrated Project IMPRESS, funded by the EU, thermophysi cal properties of two Al-Ni alloys have been investigated: Raney-nickel (Al-31.5at%Ni) and Al-25at%Ni, corresponding to the intermetallic phase Al3Ni. Transition temperatures, latent heat, heat capacity, density and electrical resistivity were measured in the solid and liquid phases. In addition, surface tension and viscosity of the melts were also determined. All quantities have been obtained as a function of temperature, in some cases also in the undercooled liquid. In this paper, we report on results obtained for the liquid phase using advanced container-based and containerless measurement methods. The obtained data yield a comprehensive characterisation of this technologically relevant class of alloys.
|
|
| 9. |
|
|
| 10. |
|
|
